Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 328-334

  Long, Xin Hua ^a   Zhang, Guo Mei ^a   Peng, Ai Fen ^b   Luo, Qing Feng ^c   Zhang, Lin ^a   Wen, Hui Cai ^a   Zhou, Rong Ping ^a   Song, Gao ^a   Zhou, Yang ^a   Liu, Zhi Li ^a  

^a NANCHANG UNIVERSITY   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Children's Hospital of Jiangxi Province   (China)

Author keywords

HER2 PI3K AKT FASN; Lapatinib; Malignant phenotype; Osteosarcoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; WESTERN BLOTTING; WOUND HEALING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FATTY ACID SYNTHASE, TYPE I; HUMANS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84891919284     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2825     Document Type: Article

References (34)

1. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011, 2005.
2. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, et al: Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96: 118-123, 2007.
3. Jawad MU, Cheung MC, Clarke J, Koniaris LG and Scully SP: Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol 137: 597-607, 2011.
4. Brand RA: 50 years ago in CORR: the present trend in treatment of osteogenic sarcoma. Clin Orthop Relat Res 467: 3038-3039, 2009.
5. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23: 8845-8852, 2005.
6. Gradishar WJ: Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol 24: 2492-2500, 2013.
7. Shanmughapriya S, Senthilkumar G, Arun S, Vinodhini K, Sudhakar S and Natarajaseenivasan K: Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India. Arch Gynecol Obstet: May 31, 2013 (Epub ahead of print).
8. Zhou BG, Liu MY, Qiu XC, Xu YM, Fan QY, Yang AG, et al: A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma. Oncol Rep 29: 276-282, 2013.
9. Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, et al: The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: a pilot study. Oncol Lett 3: 797-801, 2012.
10. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al : Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 41: 1349-1361, 2005.
11. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 24: 2360-1264, 2013.
12. Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475, 2009.
13. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA and Healey JH: Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 382: 59-65, 2001.
14. Shan LQ, Ma S, Qiu XC, Wang T, Yu SB, Ma BA, et al: A novel recombinant immuno-tBid with a furin site effectively suppresses the growth of HER2-positive osteosarcoma cells in vitro. Oncol Rep 25: 325-331, 2011.
15. Burris HA III, Hurwitz HI, Dees EC, Dowlati A, Blackwel KL, O'Neil B, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305-5313, 2005.
16. Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, et al: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23: 39-49, 2005.
17. Spector NL, Xia W, Burris H III, Hurwitz H, Dees EC, Dowlati A, et al: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23: 2502-2512, 2005.
18. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94, 2001.
19. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, et al: Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther 11: 1978-1987, 2012.
20. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al: FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13: 1114-1119, 2008.
21. Seidel J, Kunc K, Possinger K, Jehn C and Lüftner D: Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochem Biophys Res Commun 414: 226-232, 2011.
22. Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, et al: Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. J Cell Biochem: Jun 21, 2013 (Epub ahead of print). doi: 10.1002/jcb.24611.
23. Bian L, Wang T, Zhang S and Jiang Z: Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. Tumour Biol 34: 3153-3158, 2013.
24. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552, 2008.
25. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, et al: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26: 1066-1072, 2008.
26. Vandhana S, Coral K, Jayanthi U, Deepa PR and Krishnakumar S: Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim Biophys Acta 1831: 1458-1466, 2013.
27. Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y and Huang SH: Fatty acid synthase expression in osteosarcoma and its corre lation with pulmonary metastasis. Oncol Lett 4: 878-882, 2012.
28. Liu ZL, Mao JH, Peng AF, Yin QS, Zhou Y, Long XH and Huang SH: Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro. Mol Med Rep 7: 608-612, 2013.
29. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, et al: Up-regulation of acetyl-CoA carboxylase á and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 282: 26122-26131, 2007.
30. Li N, Bu X, Wu P, Wu P and Huang P: The 'HER2-PI3K/Akt-FASN Axis' regulated malignant phenotype of colorectal cancer cells. Lipids 47: 403-411, 2012.
31. Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, et al: Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 15: 7608-7615, 2009.
32. Vazquez-Martin A, Colomer R, Brunet J, Lupu R and Menendez JA: Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 41: 59-85, 2008.
33. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659, 2004.
34. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263, 2002.